Archive for the ‘Cell Therapy’ Category

Nishan - Stem Cell Therapy in Duchenne Muscular Dystrophy (DMD) - 23-04-2014
stem cell india, stem cell therapy india, stem cell in india, stem cell therapy in india, india stem cell, india stem cell therapy.

By: Stem Cell India

Read more:
Nishan - Stem Cell Therapy in Duchenne Muscular Dystrophy (DMD) - 23-04-2014 - Video

Knee Stem Cell Injections
Knee Stem Cell Injections can be a treatment for chronic pain such as Avascular Necrosis as a means of non-surgical treatment as opposed to surgery. Stem Cell Injections for Knee Osteoarthritis...

By: Dr. Lox

Read the original:
Knee Stem Cell Injections - Video

Vivek - Stem Cell Therapy in Duchenne Muscular Dystrophy (DMD)
stem cell india, stem cell therapy india, stem cell in india, stem cell therapy in india, india stem cell, india stem cell therapy.

By: Stem Cell India

View original post here:
Vivek - Stem Cell Therapy in Duchenne Muscular Dystrophy (DMD) - Video

ABC Ralph Bright harvests stem cells using the liposuction.

Serious questions have been raised about a stem cell doctor working in Western Sydney who charges $9,000 per procedure and uses methods that are untested by clinical trials.

An investigation by the ABC's 7.30 program has revealed that Dr Ralph Bright bought his liposuction-based technology from an American company.

The US company is now the subject of a multi-million dollar fraud action, which has revealed the cells being marketed as live were in fact dead.

Dr Bright, of Macquarie Stem Cells, is a former GP and self-taught cosmetic surgeon.

He has been working with stem cells for four years, treating more than 400 patients, including the late model Charlotte Dawson, cricketer Geoff Lawson and Olympic volleyballer Kerri Pottharst.

Dr Bright has licensed his methods to other practitioners around the country and because they use the patients' own cells he is not regulated by the Therapeutic Goods Administration (TGA).

Stem cells are often hailed as a miracle cure, but the nation's top stem cell scientists are warning that buyers should beware of these sorts of procedures, which are yet to be subjected to clinical trials.

Professor of Stem Cell Science at the University of Melbourne, Martin Pera, said almost all stem cell therapy was experimental.

"Actually, this whole science of cell therapy is relatively new and it's very, very important to understand that," he said.

The rest is here:
Stem cell harvesting methods used by Sydney doctor Ralph Bright untested by clinical trials

ABC Ralph Bright harvests stem cells using the liposuction.

Serious questions have been raised about a stem cell doctor working in Western Sydney who charges $9,000 per procedure and uses methods that are untested by clinical trials.

An investigation by the ABC's 7.30 program has revealed that Dr Ralph Bright bought his liposuction-based technology from an American company.

The US company is now the subject of a multi-million dollar fraud action, which has revealed the cells being marketed as live were in fact dead.

Dr Bright, of Macquarie Stem Cells, is a former GP and self-taught cosmetic surgeon.

He has been working with stem cells for four years, treating more than 400 patients, including the late model Charlotte Dawson, cricketer Geoff Lawson and Olympic volleyballer Kerri Pottharst.

Dr Bright has licensed his methods to other practitioners around the country and because they use the patients' own cells he is not regulated by the Therapeutic Goods Administration (TGA).

Stem cells are often hailed as a miracle cure, but the nation's top stem cell scientists are warning that buyers should beware of these sorts of procedures, which are yet to be subjected to clinical trials.

Professor of Stem Cell Science at the University of Melbourne, Martin Pera, said almost all stem cell therapy was experimental.

"Actually, this whole science of cell therapy is relatively new and it's very, very important to understand that," he said.

Follow this link:
Stem cells treatment used by Sydney doctor Ralph Bright 'untested' by clinical trials

TIME Health medicine Woman Receives First Stem Cell Therapy Using Her Own Skin Cells A Japanese woman is the first to receive retinal cells made from her own skin cells

Researchers at the RIKEN Center for Developmental Biology in Japan surgically transplanted a sheet of retinal pigment cells into the eye of a 70-year old woman on Friday.

The cells are the first induced pluripotent stem cells, or iPS cells, given to a human patient. They were made by Masayo Takahashi, who grew them from the patients own skin cells, which were treated with four genetic factors to revert back to an embryonic-like state. Takahashi then soaked the cells with the appropriate growth factors and other compounds so they developed into retinal pigment cells.

The patient was losing her sight due to macular degeneration, because her retinal pigment endothelial cells were damaged by an overgrowth of blood vessels. Replacing them with a new population of cells can restore her sight.

MORE: Stem-Cell Research: The Quest Resumes

Stem cell scientists are starting to test their treatments in eye-related diseases, because parts of the eye are protected from the bodys immune system, which could recognize the introduced cells as foreign and destroy them. Thats not a problem with the iPS cells, since they are made from the patients own skin cells, but its an added safety net to ensure that the therapy is safe and hopefully effective.

Because iPS cells are genetically treated to erase their skin cell development and revert them back to an embryonic-like state when they can become any type of cell, there are still concerns about their safety when transplanted into patients. The U.S. Food and Drug Administration has not yet approved a trial involving iPS cells so far, only stem cells made from excess IVF embryos have been approved for treating macular degeneration. A 19-member committee of the Japanese ministry of health approved the experimental procedure four days ago, according to Nature, after Takahashi made her case, with the help of Dr. Shinya Yamanaka of Kyoto University, who shared the 2012 Nobel Prize for discovering iPS cells.

MORE: Stem Cell Miracle? New Therapies May Cure Chronic Conditions like Alzheimers

Japans stem cell scientists are hoping the surgery is a success; the field has been struggling since a well-publicized paper about a new way to make iPS cells was retracted amid allegations of fraud.

Its not known whether the cells will continue to grow and form abnormal tumors, or whether they will migrate to other parts of the body. But now that the first patient has received them, those questions and more, about the effectiveness of stem cell therapy might be answered soon.

The rest is here:
Woman Receives First Stem Cell Therapy Using Her Own Skin Cells

GIOSTAR- STEM CELL THERAPY DR ANAND SHRIVASTAVA
Global Institute of Stem cell Therapy and Research - GIOSTAR Introduction to Stem Cell Therapy, and Dr.Anand Shrivastava - Chairman Co-founder of GIOSTAR.

By: Devang Parmar

Go here to see the original:
GIOSTAR- STEM CELL THERAPY & DR ANAND SHRIVASTAVA - Video

Freeport, Grand Bahama (PRWEB) September 08, 2014

Adult stem cell therapy for heart disease has emerged as a new treatment alternative for those living with a poor quality of life as a result of severe coronary artery disease. Okyanos is slated to begin delivering this innovative new treatment in the next several weeks, and is now screening qualified heart disease candidates. The procedure will be performed in their newly constructed state-of-the-art Phillips catheterization lab, as announced last month.

Just 50 miles from US shore, Okyanos cardiac cell therapy is available to qualified patients with advanced stages of coronary artery disease (CAD) and congestive heart failure (CHF). The screening process consists of a thorough review of your medical history by the Okyanos Chief Medical Officer and Cardiologist, Dr. Howard Walpole, as well as consultation done in conjunction with your cardiologist. You must be able to travel as the protocol is delivered in Freeport on Grand Bahama Island.

"As a leader in cardiac cell therapy, Okyanos is very excited to bring this innovative treatment and new standard of care to patients in a near-shore, regulated jurisdiction, said Matt Feshbach, CEO and co-founder of Okyanos. Our innovative treatment will restore blood flow to the heart helping it begin the process of healing itself, thereby improving the quality of life for heart disease patients who have exhausted all other options.

Over 12 million Americans suffer from some form of heart disease costing $108.9 billion dollars annually in the US alone. Several million patients have now exhausted the currently available methods of treatment but continue to suffer daily from chronic heart disease symptoms such as shortness of breath, fatigue and chest discomfort that can make simple activities challenging. Cardiac cell therapy stimulates the growth of new blood vessels which can lead to reduced angina and reduced re-hospitalizations resulting in an improvement in quality of life.

The Okyanos procedure is performed by prestigious US-licensed chief cardiologist, Dr. Howard Walpole. It is the first cardiac cell therapy procedure for heart failure and disease available outside of clinical trials in which the bodys own adult stem cells, derived from fat tissue, are injected directly into the damaged part of the heart via a catheter to restore blood flow and repair tissue damaged by a heart attack or disease.

The procedure begins with the extraction of a small amount of your body fat, a process done using advanced water-assisted liposuction technology. After separating the fat tissue using a European Union-approved cell processing device the Okyanos cardiologist immediately injects these cells into and around the low blood flow regions of the heart via a cathetera protocol which allows for better targeting of the cells to repair damaged heart tissue. Because the treatment is minimally invasive it requires that patients be under only moderate sedation. Post-procedural recovery consists of rest in a private suite for several hours that comfortably accommodates up to 3 family members.

Okyanos Heart Institute is scheduled to begin delivery in the next several weeks. Patients can contact Okyanos at http://www.Okyanos.com or by calling toll free at 1-855-659-2667.

About Okyanos Heart Institute: (Oh key AH nos) Based in Freeport, Grand Bahama, Okyanos Heart Institutes mission is to bring a new standard of care and a better quality of life to patients with coronary artery disease using cardiac stem cell therapy. Okyanos adheres to U.S. surgical center standards and is led by CEO Matt Feshbach and Chief Medical Officer Howard T. Walpole Jr., M.D., M.B.A., F.A.C.C., F.A.C.A.I. Okyanos Treatment utilizes a unique blend of stem and regenerative cells derived from ones own adipose (fat) tissue. The cells, when placed into the heart via a minimally-invasive catheterization, stimulate the growth of new blood vessels, a process known as angiogenesis. Angiogenesis facilitates blood flow in the heart and supports intake and use of oxygen (as demonstrated in rigorous clinical trials such as the PRECISE trial). The literary name Okyanos, the Greek god of the river Okeanos, symbolizes restoration of blood flow.

Continued here:
Okyanos Cardiac Cell Therapy Clinic Scheduled to Open

Stem Cell Therapy for Chronic Illness and So Called untreatable Diseases
Stem Cell Therapy with Mesenchymal stem cells are pluripotent and adult cells with fibroblastoid morphology and plasticity, toward various cell lineages such as chondrocytes, osteocytes and...

By: enjades

The rest is here:
Stem Cell Therapy for Chronic Illness and So Called untreatable Diseases - Video

Stem Cell Therapy Testimonial
Arthritis Stem Cell Therapy Testimonial. Dr. Lox can be reached at http://www.drloxstemcells.com or Call (844) 440-8503 for information on Stem Cell Therapy.

By: Dr. Lox

Excerpt from:
Stem Cell Therapy Testimonial - Video

Tampa, FL (PRWEB) September 04, 2014

On Tuesday, September 9, the Lung Institute will hold an inaugural Stem Cell Social at its Tampa location. The Lung Institute created this event to address how stem cell treatment can help lung disease sufferers. Attendees will have the opportunity to learn how stem cell therapy can help, as well as set up a free consultation. In addition, a number of recent patients will be present to share how stem cell therapy has personally impacted their lives by repairing damaged lung tissue and improving function.

As a leader in regenerative medicine, the Lung Institute has provided almost 300 stem cell treatments to lung disease patients who previously had no hope for better breathing and regaining quality of life. The Lung Institute treats lung diseases including pulmonary fibrosis and chronic obstructive pulmonary disease (COPD), a progressive disease that causes difficulty breathing, and is the third leading cause of death in the United States.

Led by Dr. Burton Feinerman, a world-renowned physician in the field of regenerative medicine, the Lung Institute offers minimally invasive, and outpatient stem cell treatments for patients with a variety of debilitating lung diseases. Stem cells are taken from the patients own blood or fat tissue. The treatments cue healing processes in the lungs, allowing patients to get back to normal, everyday activities and breathe easier.

Patients from the United States and around the world have traveled to Tampa to receive treatment. We provide hope to our patients, and an improved quality of life, said Dr. Feinerman. Our inaugural stem cell social is the perfect opportunity to learn about this innovative treatment option that can literally change a persons life.

Join the Lung Institute for its inaugural Stem Cell Social:

When: Tuesday, September 9, 4 p.m.7 p.m. Where: Lung Institute, 201 E. Kennedy Blvd., Suite 425, Tampa, FL 33602 What: A presentation by Dr. Feinerman and feedback from his patients about stem cell therapy. In addition, there will be refreshments and three grand-prize winners will receive $3,000 gift cards toward the purchase of treatment at the Lung Institute*! RSVP: Space is limited with only 30 spots available. Please RSVP to (855) 469-5864.

About the Lung Institute At the Lung Institute, we are changing the lives of hundreds of people across the nation through the innovative technology of regenerative medicine. We are committed to providing patients a more effective way to address pulmonary conditions and improve quality of life. Our physicians, through their designated practices, have gained worldwide recognition for the successful application of revolutionary minimally invasive stem cell therapies. With over a century of combined medical experience, our doctors have established a patient experience designed with the highest concern for patient safety and quality of care. For more information, visit our website at LungInstitute.com, like us on Facebook, follow us on Twitter or call us today at (855) 469-5864.

More:
Lung Institute Holds Inaugural Stem Cell Social

The treatment involves injecting up to 20 million stem cells into patients' brains. It was tested on patients at Glasgow's Southern General Hospital in 2012.

The Surrey-based company said it would work at 10 sites across the UK, including the Southern General, on a Phase II efficacy study of the ReN001 treatment involving 41 patients.

Loading article content

The treatment is designed to deliver a meaningful improvement in upper limb function in disabled stroke patients.

In May, the company said data from a long-term follow- up involving 11 patients included in a Phase I safety study of ReN001 at the Glasgow hospital observed sustained reductions in neurological impairment and spasticity in most patients. No cell-related or immunological adverse events were reported .

Yesterday, Reneuron said it has also started a Phase I safety study at Ninewells Hospital in Dundee of its ReN009 therapy for people with lower limb ischaemia. It will involve nine patients.

Reneuron says the disease is common in patients with diabetes and can lead to amputation of the limb.

Visit link:
Reneuron tests stem cell stroke treatment

Boy Scout Troop 286 Icebucket Challenge for the Scoutmaster
Ice Bucket Challenge Completed! With a whole lot of help from my Scouts! Donation went to the Midwest Stem Cell Therapy Center at KU Med in Kansas City. They do some terrific work there and...

By: Scott Medlock

Excerpt from:
Boy Scout Troop 286 Icebucket Challenge for the Scoutmaster - Video

STEM CELL THERAPY: with DR ANDREW J. ROCHMAN
Dr. Andrew J Rochman is a leader in advanced surgical techniques, a native New Yorker and a Board-Certified Surgeon. His current undertaking involves promoting an educational advocacy in MODERN...

By: Modern Pain Relief

Excerpt from:
STEM CELL THERAPY: with DR ANDREW J. ROCHMAN - Video

ABC Kellie van Meurs (3rd from R) died of a heart attack last month while receiving stem cell treatment in Moscow.

Rogue operators in Australia and overseas are charging thousands of dollars for ineffectual stem cell treatments, a leading stem cell research group has warned.

And Stem Cells Australia says there is a growing number of patients going overseas for stem cell treatments which are limited in Australia.

A loophole in the therapeutic goods legislation means that doctors are legally allowed to treat patients, both here and overseas, with their own stem cells even if that treatment is unsafe or has not been proven effective through clinical trials.

Stem Cells Australia believes that dozens of doctors in Australia offer the questionable treatments.

"They're selling treatment without any proof of benefit, and without any proof of safety," Associate Professor Megan Munsie, a stem cell biologist at the University of Melbourne, told 7.30.

Annie Leverington was diagnosed with multiple sclerosis in 2007.

She was once a talented flamenco dancer and worked as a court stenographer.

But in 2002 she noticed something was wrong when her fingers started to "drop" during long trials.

Then her feet started to go.

More here:
Rogue stem cell therapy operators charging thousands for ineffective treatments, researchers say

Why not embryonic stem cell
Why not embryonic stem cell ? In conversation with Dr Alok Sharma (MS, MCh.) Professor of Neurosurgery Head of Department, LTMG Hospital LTM Medical College, Sion, Mumbai. Stem Cell Therapy...

By: Neurogen Brain and Spine Institute

Continue reading here:
Why not embryonic stem cell - Video

what is the procedure of stem cell therapy for autism spectrum disorder
What is the procedure of stem cell therapy for autism spectrum disorder? In conversation with Dr Alok Sharma (MS, MCh.) Professor of Neurosurgery Head of Department, LTMG Hospital LTM Medical...

By: Neurogen Brain and Spine Institute

Go here to read the rest:
what is the procedure of stem cell therapy for autism spectrum disorder - Video

Oldsmar, FL (PRWEB) August 22, 2014

This funding was made through an additional investment in Cryo-Cells cell therapy research affiliate, Saneron CCEL Therapeutics, Inc. in the form of a convertible promissory note purchase agreement.

Cryo-Cell is extremely pleased to collaborate with Saneron on several fronts to enable the filing of an IND, which we hope will lead to regenerative therapies using cord blood to treat devastating neurodegenerative diseases such as ALS, David Portnoy, Chairman and Co-CEO of Cryo-Cell, stated. He continued, Although this is only the next step, if Sanerons cord blood product ultimately is successfully approved by the FDA to treat ALS, Saneron will indeed prove to be a very valuable corporate asset for Cryo-Cell.

With these funds, Saneron anticipates filing an IND application in the fourth quarter of 2014. The IND for the FDA will be for a Phase I Safety trial enrolling 12 patients that have been diagnosed with ALS, said Nicole Kuzmin-Nichols, President & COO of Saneron. The study will involve the administration of U-CORD-CELL, Sanerons proprietary mononuclear enriched cell fraction of umbilical cord blood to be processed in Cryo-Cells GMP laboratory.

Sanerons sponsored preclinical studies using U-CORD-CELL have demonstrated efficacy in various disease models including: ALS, stroke, myocardial infarction, and Alzheimers disease. In particular, the Cryo-Cell affiliate has demonstrated that a single intravenous administration of U-CORD-CELL can delay disease progression and extend lifespan in a preclinical ALS animal model.

Cryo-Cell is excited that Sanerons U-CORD-CELL processed cell fraction has shown improved efficacy in the ALS preclinical model when previously compared to commonly utilized cord blood cell processing procedures used in the cord blood banking industry.

ALS is a devastating disease that is a rapidly progressive, invariably fatal neurological disease that attacks the nerve cells (neurons) responsible for controlling voluntary muscles (muscle action we are able to control, such as those in the arms, legs, and face). The disease belongs to a group of disorders known as motor neuron diseases, which are characterized by the gradual degeneration and death of motor neurons. According to the ALS Association, in the U.S., approximately 30,000 people have ALS and each year 5,000 people are diagnosed with the disease.

About Cryo-Cell International

Founded in 1989, (OTCQB:CCEL) Cryo-Cell International, Inc. is the world's first private cord blood bank. More than 500,000 parents from 87 countries trust Cryo-Cell to preserve their family members' stem cells. Cryo-Cell's mission is to provide clients with state-of-the-art stem cell cryopreservation services and support the advancement of regenerative medicine. Cryo-Cell operates in a facility that is FDA registered, cGMP-/cGTP-compliant and is licensed in all states requiring licensure. Besides being AABB accredited as a cord blood facility, Cryo-Cell is also the first U.S. (for private use only) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization. In addition, Cryo-Cell is ISO 9001:2008 certified by BSI, an internationally recognized, quality assessment organization. Cryo-Cell is a publicly traded company, OTCQB: CCEL. For more information, please visit http://www.cryo-cell.com.

About Saneron CCEL Therapeutics, Inc.

Continued here:
Cryo-Cell Provides Funding for Cord Blood Clinical Trial Application to Treat ALS

Novartis ( NVS ) recently entered into an investment and option agreement with Israel-based Gamida Cell, a company which focuses on stem cell expansion technologies and therapeutic products.

As per the terms of the agreement, Novartis will invest $35 million in Gamida Cell. In exchange, Novartis will receive a 15% stake in Gamida Cell and an option to fully acquire the company.

The option for full acquisition is exercisable for a limited period of time following achievement of certain milestones in connection with the development of pipeline candidate, NiCord. These milestones are expected to be achieved during 2015. Novartis will also be required to pay the other shareholders in Gamida Cell approximately $165 million upon exercising the option along with potential milestone payments of $435 million.

We note that Gamida Cell is developing stem cell therapy for the potential treatment of blood cancers, solid tumors, non-malignant hematological diseases such as sickle cell disease and thalassemia, neutropenia and acute radiation syndrome, autoimmune diseases and genetic metabolic diseases as well as conditions that can be helped by regenerative medicine.

The company is currently evaluating NiCord for the potential treatment of hematological malignancies such as leukemia and lymphoma in a phase I/II study using its proprietary NAM technology.

Meanwhile, enrolment is on for the company's phase I/II study on NiCord for pediatric sickle cell disease.

We remind investors that Novartis has been taking strategic steps to realign its portfolio in order to focus on its core portfolio of pharmaceuticals, eye care and generics. Novartis' recent deal to acquire oncology products from GlaxoSmithKline ( GSK ) and the divestiture of the Vaccines business is a step in the right direction.

Novartis, a large-cap pharma, currently carries a Zacks Rank #3 (Hold). Right now, Allergan ( AGN ) and AbbVie ( ABBV ) look well positioned among the large-cap pharmas. While Allergan carries a Zacks Rank #1 (Strong Buy), AbbVie is a Zacks Rank #2 (Buy) stock.

NOVARTIS AG-ADR (NVS): Free Stock Analysis Report

ABBVIE INC (ABBV): Free Stock Analysis Report

Go here to read the rest:
Novartis to Invest $35M in Gamida Cell for 15% Equity - Analyst Blog

PUBLIC RELEASE DATE:

12-Aug-2014

Contact: Meng Zhao eic@nrren.org 86-138-049-98773 Neural Regeneration Research

Mammalian adult central nerve system (CNS) injuries are devastating because of the intrinsic difficulties for effective neuronal regeneration. The greatest problem to be overcome for CNS recovery is the poor regeneration of neurons and myelin-forming cells, oligodendrocytes. Endogenous neural progenitors and transplanted exogenous neuronal stem cells can be the source for neuronal regeneration. However, because of the harsh local microenvironment, they usually have very low efficacy for functional neural regeneration which cannot compensate for the loss of neurons and oligodendrocytes. Glial cells (including astrocytes, microglia, oligodendrocytes and NG2 glia) are the majority of cells in CNS that provide support and protection for neurons. Inside the local microenvironment, glial cells largely influence local and transplanted neural stem cells survival and fates. This review critically analyzes current finding of the roles of glial cells in CNS regeneration, and highlights strategies for regulating glial cells' behavior to create a permissive microenvironment for neuronal stem cells. The Perspectives paper published in Neural Regeneration Research (Vol. 9, No. 13, 2014).

###

Article: "Stem cell therapy for central nerve system injuries: glial cells hold the key" by Li Xiao, Chikako Saiki, Ryoji Ide (1 Pharmacology Department, The Nippon Dental University, School of Life Dentistry at Tokyo, Tokyo, Japan; 2 Physiology Department, The Nippon Dental University, School of Life Dentistry at Tokyo, Tokyo, Japan).

Xiao L, Saiki C, Ide R. Stem cell therapy for central nerve system injuries: glial cells hold the key. Neural Regen Res. 2014;9(13):1253-1260.

Contact: Meng Zhao eic@nrren.org 86-138-049-98773 Neural Regeneration Research http://www.nrronline.org/

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

View original post here:
Stem cell therapy for central nerve system injuries: Glial cells hold the key

Kasi kaka-quit ko lang ng smoking, Lorna Tolentino proudly announces.

The 52-year-old actress also adds, Mag-wa-one month na sa August 14.

Asked whether shes having a hard time adjusting her lifestyle, she says, Ay no, hindi naman talaga ako ganun Im not really talaga sobrang sobrang smoker.

Right now, Lorna is taking supplements such as vitamin B1, B complex, glutathione, and mangosteen and malunggay capsules.

Siyempre nung nag-50 ako, mas iniisip ko na mas tumagal pa.

Kasi siyempre, 'di ba, gone too soon si Rudy [Fernandez], kaya siyempre kailangan mas mahaba pa, lalo na because of my apo, yun ang nag-i-inspire sa akin, she confesses.

When asked whether shes ok with Lyla Victoria, Raphael's (Lorna's eldest son) daughter, entering showbiz, Lorna answers, Commercial kung meron, oo tatangapin ko.

Lorna enthusiastically talks about her two-year-old apo, whom she refers to as still being in her makulit stage, Shes ok, actually yung kanya intellectual [maturity] ano, something na pinapaano sa mga doctor, for four years old na.

She also complements Leana, Lylas mother, for teaching her grandchild, Talagang kinu-congratulate ko si Leana, because shes a teacher, talagang mas kaya niya i-guide.

STEM CELL THERAPY.Lorna Tolentino, who has undergone stem cell therapy, narrates how the procedure helped her health concerns.

Continue reading here:
Lorna Tolentino reveals the secret to her youthful looks

A stroke therapy using stem cells extracted from patients' bone marrow has shown promising results in the first trial of its kind in humans.

Five patients received the treatment in a pilot study conducted by doctors at Imperial College Healthcare NHS Trust and scientists at Imperial College London.

The therapy was found to be safe, and all the patients showed improvements in clinical measures of disability.

The findings are published in the journal Stem Cells Translational Medicine. It is the first UK human trial of a stem cell treatment for acute stroke to be published.

The therapy uses a type of cell called CD34+ cells, a set of stem cells in the bone marrow that give rise to blood cells and blood vessel lining cells. Previous research has shown that treatment using these cells can significantly improve recovery from stroke in animals. Rather than developing into brain cells themselves, the cells are thought to release chemicals that trigger the growth of new brain tissue and new blood vessels in the area damaged by stroke.

The patients were treated within seven days of a severe stroke, in contrast to several other stem cell trials, most of which have treated patients after six months or later. The Imperial researchers believe early treatment may improve the chances of a better recovery.

A bone marrow sample was taken from each patient. The CD34+ cells were isolated from the sample and then infused into an artery that supplies the brain. No previous trial has selectively used CD34+ cells, so early after the stroke, until now.

Although the trial was mainly designed to assess the safety and tolerability of the treatment, the patients all showed improvements in their condition in clinical tests over a six-month follow-up period.

Four out of five patients had the most severe type of stroke: only four per cent of people who experience this kind of stroke are expected to be alive and independent six months later. In the trial, all four of these patients were alive and three were independent after six months.

Dr Soma Banerjee, a lead author and Consultant in Stroke Medicine at Imperial College Healthcare NHS Trust, said: "This study showed that the treatment appears to be safe and that it's feasible to treat patients early when they might be more likely to benefit. The improvements we saw in these patients are very encouraging, but it's too early to draw definitive conclusions about the effectiveness of the therapy. We need to do more tests to work out the best dose and timescale for treatment before starting larger trials."

Continue reading here:
Stem cells show promise for stroke in pilot study

PHYTOSCIENCE PHILIPPINES DOUBLE SKIN CELL THERAPY REVIEW
PHYTOSCIENCE PHILIPPINES DOUBLE SKIN CELL THERAPY REVIEW A RARE OPPORTUNITY TO ALL FILIPINOS BE A PART OF THE PHYTOSCIENCE PIONEERING TEAM 2013 Best Selling ...

By: phytoscience double stem cell philippines

The rest is here:
PHYTOSCIENCE PHILIPPINES DOUBLE SKIN CELL THERAPY REVIEW - Video

(PRWEB UK) 7 August 2014

BioEden the specialist tooth stem cell bank stands by its pledge to make personalised stem cell therapy an affordable reality by launching Access Membership at just 5 per month.

With stem cell therapy holding the promise of longer and better lives in the future, the cost and the ease of finding a stem cell match has been an issue, given that the cost of private stem cell banking requires an initial cash outlay of up to 4000.

Not any more.

BioEden the leading specialist tooth stem cell bank, has added Access Membership to parents finding themselves financially unable to bank their child's cells for future use. "It doesnt sit well with us that a parent could be unable to access what could be a life saving service for their child, for financial reasons," said Group CEO Mr Tony Veverka.

Parents can access the stem cell banking service for just 5 per month, and can become a member of the plan as soon as the baby is born. To date the option for stem cell banking at birth has been umbilical cord blood banking, an invasive process which provides haemopoetic stem cell banking at a cost.

Now parents have the option to choose tooth stem cell banking or to add this to cord blood banking at a very low monthly cost.

Tooth stem cells have considerable advantages over cord blood cells;

And now, thanks to BioEden, cost doesnt have to be a barrier.

So how can 5 a month give access to such a specialist service?

More:
BioEden fights the financial cost of stem cell banking by bringing their specialist service to the people for just 5 ...

Knee arthritis 28 months after stem cell therapy by Harry Adelson, N.D.
Cory describes his outcome from a single bone marrow/adipose stem cell treatment for his arthritic knees by Harry Adelson, N.D. http://www.docereclinics.com.

By: Harry Adelson, N.D.

See the article here:
Knee arthritis 28 months after stem cell therapy by Harry Adelson, N.D. - Video